Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 15, 2024HaematologicaOpen Access

Lenalidomide, rituximab, and methotrexate are effective in newly diagnosed primary central nervous system lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

XYXianggui YuanSecond Affiliated Hospital of Zhejiang UniversityYXYaping XieHangzhou First People's HospitalNXNengwen XuNanfang Hospital

Discussion

Loading...

Member takes

Key Points

Key points are not available for this paper at this time.

Cite This Study

Yuan et al. (2024) studied this question.

synapsesocial.com/papers/6aa9460e6dc8754dbe62ebadhttps://doi.org/10.3324/haematol.2023.284834
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1An Overview of Lenalidomide in Combination with Rituximab for the Treatment of Adult Patients with Follicular Lymphoma: The Evidence to Date2021 · 6 citations
  2. 2Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells2008 · 438 citations
  3. 3Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience2003 · 859 citations
  4. 4Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of concept’ phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)2019 · 246 citations
  5. 5Management and outcome of primary CNS lymphoma in the modern era2020 · 253 citations